ABC | Volume 112, Nº5, Maio 2019

Atualização Atualização das Diretrizes em Cardiogeriatria da Sociedade Brasileira de Cardiologia - 2019 Arq Bras Cardiol. 2019; 112(5):649-705 305. Ruigómez A, Johansson S,WallanderMA, EdvardssonN, García Rodríguez LA. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. Int J Cardiol. 2009;136(2):186-92. 306. Aronow WS. Management of the older person with atrial fibrillation. J Gerontol A Biol Sci Med Sci. 2002;57(6):M352-63. 307. Desai Y, El-Chami MF, Leon AR, Merchant MF. Management of atrial fibrillation in elderly adults. J AmGeriatr Soc. 2017;65(1):185-93. 308. Patel PA, Ali N, Hogarth A, TayebjeeMH. Management strategies for atrial fibrillation. J R Soc Med. 2017;110(1):13-22. 309. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016;388(10046):818-28. 310. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet. 2016;388(10046):829-40. 311. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Hillege HL, et al; RACE II Investigators. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II Study. Eur J Heart Fail. 2013;15(11):1311-8. 312. VanGelder IC, GroenveldHF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73. 313. MagalhãesLP,FigueiredoMJ,CintraFD,SaadEB,KuniyishiRR,TeixeiraRA, et al. II Diretrizes brasileiras de fibrilação atrial. Arq Bras Cardiol. 2016;106 (4 Supl. 2):1-22. 314. Marshall HJ, Harris ZI, Griffith MJ, Gammage MD. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. Heart. 1998;79(6):543-7. 315. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: a systematic review. J Am Coll Cardiol. 2012;59(8):719-26. 316. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A et al.; AFFIRM Investigators. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8. 317. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al.; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS Guideline for theManagement of PatientsWith Atrial Fibrillation: Executive Summary: a Report of the AmericanCollege of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-104. 318. Calkins H, Kuck KH, Cappato R, Brugada J, CammAJ, Chen SA et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of theHeart RhythmSociety (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) andtheEuropeanCardiacArrhythmiaSociety (ECAS);and incollaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association,theEuropeanCardiacArrhythmiaSociety,theEuropeanHeart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632-96. 319. Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114(4):826-34. 320. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. 321. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al.; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. 322. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5(1):85-93. 323. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70. 324. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330-1393. 325. January CT, Wann LS, Calkins H, Field ME, Chen LY, Furie KL et al. 2019 AHA/ACC/HRS FocusedUpdate of the 2014AHA/ACC/HRSGuideline for theManagement of PatientsWith Atrial Fibrillation. Heart Rhythm. 2019. 326. Lee JM, Shim J, Uhm JS, Kim YJ, Lee HJ, Pak HN et al. Impact of increased orifice size and decreased flow velocity of left atrial appendage on stroke in nonvalvular atrial fibrillation. Am J Cardiol. 2014;113(6):963-9. 327. Gupta DK, Shah AM, Giugliano RP, Ruff CT, Antman EM, Grip LT et al.; Effective aNticoaGulation with factor xA next GEneration in AF- Thrombolysis In Myocardial Infarction 48 Echocardiographic Study Investigators.Leftatrialstructureand function inatrial fibrillation:ENGAGE AF-TIMI 48. Eur Heart J. 2014;35(22):1457-65. 328. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34(14):1041-9. 329. Ansell J, Hirsh J, Dalen D, Bussey H, Anderson D, Poller L et al. Managing oral anticoagulant therapy. Chest. 2001;119(1 Suppl):22S-38S. 330. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta- analysis of randomised trials. Lancet. 2014;383(9921):955-62. 331. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review andmeta-analysis. Circulation. 2015;132(3):194-204. 332. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-20. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 705